Combining IP-10 Gene Therapy with Gemcitabine for Cancer Treatment
Author Information
Author(s): Mei Kai, Wang Lian, Tian Ling, Yu Jingrui, Zhang Zhixuan, Wei Yuquan
Primary Institution: Sichuan Cancer Hospital, Chengdu, PR China
Hypothesis
Can the combination of IP-10 gene therapy and gemcitabine enhance antitumor effects in murine models?
Conclusion
The combination of IP-10 gene therapy and gemcitabine effectively inhibits tumor growth and prolongs survival in mice.
Supporting Evidence
- Combination therapy resulted in 85% tumor volume inhibition in H22 tumor models.
- Survival times increased significantly in the combination therapy group compared to controls.
- Angiogenesis was significantly inhibited in tumors treated with the combination therapy.
Takeaway
This study shows that using a special gene therapy along with a common cancer drug can help fight tumors better in mice.
Methodology
Mice were treated with IP-10 plasmid and gemcitabine, and tumor growth and survival were measured.
Limitations
The study was conducted only in murine models, which may not fully represent human responses.
Participant Demographics
C57BL/6 and BALB/c female mice, approximately 20g body weight.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website